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SIREN, ANNA-LEENA, AND GIORA FEUERSTEIN. E{fects of 
PAF and BN 52021 on cardiac function and regional blood flow 
in conscious rats. Am. J. Physiol. 257 (Heart Circ. Physiol. 26): 
H25-H32, 1989.-The effect of intravenous injections (0.1-3 
nmol/kg) of platelet-activating factor (P AF) on blood pressure, 
heart rate, cardiac output, and blood flow (hindquarter, renal, 
mesenteric) were studied in conscious rats. PAF decreased 
blood pressure and total peripheral reistance (TPR) but in-
creased heart rate; cardiac output was reduced by the highest 
dose. Low doses of P AF increased blood flow and decreased 
vascular resistance in all vascular beds, whereas high doses 
reduced mesenteric blood flow in part by increasing mesenteric 
vascular resistance. The hypotensive and cardiac effects of P AF 
were blocked by intravenous infusions of the selective P AF-
receptor antagonists, 15 mg/kg BN 52021 and 1 mg/kg SDZ 
63-441. BN 52021 also attenuated the hindquarter and renal 
responses to PAF, but the mesenteric responses remained rel-
atively unchanged. The results indicate that PAF is a potent 
vasodilator of mesenteric > hindquarter = renal vessels at low 
doses and a cardiac depressant at high doses. A therapeutic role 
for the PAF antagonists BN 52021 and SDZ 63-441 is suggested 
in endotoxemia, anaphylaxis, and other disease states in which 
increased release of P AF contributes to key hemodynamic 
derangements. 
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PLATELET-ACTIVATING FACTOR (PAF) is a glycerophos-
pholipid produced and released from stimulated cells 
such as basophils, macrophages, platelets, polymorpho-
nuclear neutrophils, endothelial cells, and mast cells (29). 
Systemic administration of P AF induces hypotension in 
various animal species (for review see Ref. 8). Decreases 
in arterial pressure, cardiac output, and total peripheral 
resistance after P AF administration have been reported 
in the anesthetized rat and dog (12, 22, 30). Although 
the effects of P AF on gross cardiovascular variables have 
been repeatedly reported, only a few reports to date have 
studied the discrete organ blood flow changes after P AF 
administration in intact animals. In the anesthetized 
dog, PAF decreased renal blood flow (2, 30), whereas 
vasodilation was reported in the femoral artery (27). In 
the anesthetized domestic pig, P AF produced a dual 
effect on coronary circulation: vasodilation followed by 
vasoconstriction (9). Decreases in blood flow to brain, 
heart, kidneys, lungs, and spieen in response to P AF 
infusions were described in the anesthetized sponta-
neously hypertensive rat (SHR, Ref. 12). However, none 
of the previous sturlies attempted to examine the relative 
contribution of cardiac output and organ blood flow in 
PAF -induced circulatory shock. Furthermore, in the spe-
cies studied previously, i.e., dog, pig, guinea pig, and 
rabbit, P AF is a potent aggregator and activator of plate-
lets and white blood cells; vasoactive substances (e.g., 
thromboxane A2 and leukotrienes) released from these 
cellular elements were shown to mediate most of the 
PAF effects (8, 9, 13, 18, 27). Rat platelets like those of 
humans, are relatively resistant to PAF actions (8, 23), 
and therefore the rat could serve as a useful model to 
study blood vessel responses to P AF independent of 
platelet aggregation. 
The present study examined the systemic and regional 
hemodynamic changes that accompany the hypotensive 
effect of PAF in conscious rats. In addition, the influ-
ences of specific PAF-receptor antagonists, BN 52021 
(4), SDZ 63-441 (13), and the benzodiazepine alprazolam 
(16), on various blood vessel and cardiac responses to 
P AF were also studied. 
MATERIALS AND METHODS 
Male Sprague-Dawley rats (300-310 g) were purchased 
from Taconic Farms (Germantown, NY) and kept at 
22oC andin a 12-h Iight-dark cycle. After surgical oper-
ations, the rats were housed individually in plastic cages 
(21 X 27 X 16 cm, W X L X H) with food and water ad 
libitum and monitared daily for adequate recovery from 
surgery. 
Measurement of cardiac output. The rats were anesthe-
tized with an intramuscular injection of 130 mg/kg ket-
amine and 1.3 mg/kg acepromazine, and PE-50 catheters 
were inserted into femoral vessels. The catheters were 
tunneled under the skin and exited at the nape of the 
neck. An incision was made at the midline of the neck 
from the cricoid to the clavicle, and a PE-50 catheter 
was inserted into the right atrium through the external 
jugular vein. The left common carotid artery was exposed 
and ligated, and a thermistor (MX2-780-33 model 
THMP f 1.5, Teflon reusable, Columbus Instruments, 
OH) was advanced through the carotid into the ascending 
aorta (placement above the aortic valve was confirmed 
in each animal at the end of the experiment and by the 
shape of the dilution curve before the probe was finally 
H25 
H26 CARDIAC AND VASCULAR EFFECTS OF PAF 
sutured to the neck muscles). The jugular vein catheter 
and the thermistor were tunneled under the skin to the 
nape of the neck. All catheters and the probe wire were 
secured by a soft spring wire attached to the animal's 
neck with an adhesive collar. Twenty-four hours after 
the surgery, the arterialline was connected to a pressure 
transducer (Narco Bio-Systems model RP 1500i) coupled 
to a strain gauge coupler (Narco Bio-Systems type 7032). 
Blood pressure (mean, systolic, diatolic, pulse) and heart 
rate were continuously recorded on a N arcotrace 80 
computerized physiograph and sampled automatically at 
30- to 60-s intervals by a Northstar-Hazeltine computer. 
The cardiac output was measured by thermodilution 
technique as previously described (25). In brief, the 
thermistor was attached to the computerized Cardiomax 
II (CMX2-780-k with microprobe option R, Columbus 
Instruments). The dead space of the venous line was first 
flushed with 0.05 ml of 0.9% (wt/vol) NaCl (saline) at 
room temperature (22°C); after a brief stabilization 
period an additional injection of 0.2 ml normal saline 
(22°C) was rapidly injected using a 1-ml syringe. For 
cardiac output measurement a control period of 15 min 
included two or three cardiac output recordings to test 
for consistency and placement of the probe. During this 
period control values for blood pressure and heart rate 
were also collected. The timer of the automatic data 
collection was started, and data points were collected 
immediately before and 30 s, 2, 5, 10, 20, and 30 min 
after the P AF injection. Total peripheral resistance index 
(TPRI) was calculated by dividing the mean arterial 
pressure by the cardiac output; values of cardiac output 
and TPRI were further indexed per unit of weight (kg). 
Measurement of organ blood flow. The directional 
pulsed-Doppler method was selected to measure organ 
blood flow in the hindquarter, renal, and mesenteric 
vessels. Although it does not allow quantitative blood 
flow monitoring, this method is superior compared with 
other available techniques; because it can be used chron-
ically in conscious animals, it allows continuous on-line 
recording of blood flow and detections of instantaneous 
and transient changes in blood flow within seconds after 
the drug administration. Haywood and co-workers (14) 
have shown that the velocity signals recorded from the 
Doppler flow probes are directly and reliably propor-
tional to changes in true volume flow measured by elec-
tromagnetic flowmetry. 
The rats were anesthetized with ketamine-aceproma-
zine as described in Measurement of cardiac output. A 
midline laparotomy was made, and the left renal and 
superior mesenteric arteries and lower abdominal aorta 
above its bifurcation were carefully isolated under a 
dissecting microscope. Doppler flow probes (Valpey-
Fisher, Hopkinton, MA) were then loosely sutured 
around each vessel. The insulated wire Ieads were fixed 
to the back muscles, tunneled under the back skin to exit 
at the neck, and soldered to a receptacle that was then 
attached to the skull with small screws and dental acrylic. 
The animals were allowed to recover from the surgery 
for 7 days. Twenty-four hours before the experiment, the 
rats were reanesthetized with halothane (2% in 02), and 
the femoral artery and vein were catheterized with PE-
50 tubing. The catheters were tunneled under the back 
skin, exited at the nape of the neck, and secured by a 
soft spring wire as described above. 
On the day of the experiment, the arterial catheter was 
connected to a pressure transducer (Narco), and blood 
pressure and heart rate were continuously recorded on 
the N arcotrace 80 physiograph. A cable connecting the 
blood flow recepticle and the Doppler flowmeter (Uni-
versity of Iowa, Bioengineering Facility, model 545C-4) 
was attached to the animal, and the mean blood flow was 
continuously recorded on the physiograph. Vascular re-
sistance was calculated by dividing the mean arterial 
pressure by blood velocity (Doppler shift in kHz) as 
earlier described (14, 25). Changes in blood flow and 
vascular resistance areexpressedas a percent of control 
values. 
Drugs used. Pure synthetic 1-0-hexadecyl-2-acetyl-
sn-glycero-3-phosphorylcholine (PAF) was kindly pro-
vided by Dr. F. Snyder, Oak Ridge Associated Universi-
ties, Oak Ridge, TN. P AF was dissolved in saline to a 
stock solution of 100 nmol/ml, which was kept frozen 
(-70°C) until used, and diluted to a final volume of 100 
~l per injection. Pure powdered BN 52021 [9H1,7a-
(epoxymethano) -1H,6aH -cyclopenta[ c ]furo[2,3-b] furo-
[3 1 ,2 1 ,3,4] cyclopenta [ 1,2-d] furan-5,9,12-(4H)trione, 
3-tert-butylhexahydro-4,-7b,-11hydroxy-8methyl] was 
kindly provided by Dr. P. Braquet, IHB Research Lab-
oratories, France. For administration to the rat, BN 
52021 was first dissolved in 50 ~l of 50% dimethyl sulf-
oxide (DMSO) and further diluted with 1 ml of normal 
saline. The pH was adjusted to the range of 7-8 by 
titration with 10 N NaOH. Alprazolam (kindly provided 
by Upjohn, Kalamazoo, MI) was first dissolved in abso-
lute ethanol and propyleneglycol and further diluted in 
saline. The concentrations ofthe above mentioned chem-
ieals in the final solution were 10 ethanol, 40 propylene-
glycol, and 50% saline. Cis-(±)-1-[2-[hydroxy[[tetra-
hydro-5-[ (octadecylaminocarbonyl)oxy] methyl]-furan-
2-yl]methoxyphosphinyloxy]ethyl]quinolinium hydrox-
ide (SDZ 63-441, Sandoz Research Institute, East Han-
over, NJ) was dissolved in saline immediately before 
injection. 
lncreasing doses of 0.1-3 nmol/kg P AF were injected 
intravenously at 30- to 90-min intervals. The effect of 
the preceding dose had completely subsided before the 
administration of each new dose; 15 mg/kg BN 52021 
was injected 15 min before 0.3-3 nmol/kg PAF, 3 mg/kg 
alprazolam was injected 20 min before 1-3 nmol/kg P AF, 
and SDZ 63-441 was injected 2 min before 1 nmol/kg 
PAF. 
Statistical analysis of data. Data in text and figures are 
represented as means ± SE for the given number of rats. 
One-way analysis ofvariance (ANOVA) followed by Stu-
dent-N ewman-Keuls test or Kruskal-W allis test (28) was 
used for statistical analysis of the data. A significant 
difference was accepted at P < 0.05. 
RESULTS 
Effects of PAF on systemic hemodynamic variables. The 
base-line blood pressure and heart rate were not influ-
enced by repeated injections of PAF (Fig. 1). The PAF 
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FIG. 1. Dose-response effect of PAF on mean arterial pressure (MAP), heart rate (HR), cardiac index (Cl), and 
total peripheral resistance index (TPRI) in conscious rats. Increasing doses of 0.3-3 nmol/kg PAF were injected 
intravenously at 60- to 90-min intervals. Values indicate means ± SE. No. of rats is given in parentheses. Asterisks 
denote statistical significance from control by Kruskal-Wallis test. 
doses up to 1 nmol/kg had no effect on hematocrit. The 
hematocrit before tbe 1-nmol/kg dosewas 43 ± 2%, and 
60 min after this dose it was 44 ± 2%. PAF (1- to 3-
nmol/kg) induced a dose-related decrease in mean arte-
rial pressure (MAP) and increased beart rate (Fig. 1). 
The maximum bypotensive and tachycardic effects after 
each dose of P AF were achieved in 30-60 s and subsided 
in 5-15 min. The lower doses (0.1-0.3 nmol/kg) bad no 
effect on blood pressure (maximum cbanges of -2 ± 3 
and -10 ± 4 mmHg, respectively), but the 0.3-nmol/kg 
dose induced a significant increase in beart rate (Fig. 1). 
Tbe base-line values of cardiac index before PAF ad-
ministration ranged from 380 to 458 ml- min-1 • kg-1• The 
range of the cardiac index values in tbe present study is 
weil in agreement witb our previous findings (25) as weil 
as those of others utilizing the thermodilution method 
(21). Tbe 1-nmol/kg dose of PAF decreased TRPI with 
no consistent effect on cardiac index; in five of 12 ani-
mals, P AF increased cardiac index ( +91 ± 21 ml- kg-1 • 
min-1), whereas tbe otber seven animals reacted to tbe 
PAF injections witb a decrease in cardiac index ( -104 ± 
22 ml- min- 1 -kg- 1). The higbest dose produced a marked 
decrease in cardiac index (Fig. 1). Tbe fall in TPRI 
became apparent with the maximum bypotensive re-
sponse 30 s after P AF administration and subsided in 5 
min. The 3-nmol/kg dose of PAF first transiently de-
creased and then increased TPRL 
Effect of PAF antagonists on systemic hemodynamic 
responses to PAF. Fifteen milligrams per kilogram of BN 
52021 or 1 mg/kg SDZ 63-441 bad no effect on the basal 
values of blood pressure, beart rate, cardiac index, or 
TPRI, whereas alprazolam significantly decreased MAP 
and increased heart rate resulting in a significantly lower 
MAP and a bigber beart rate before P AF administration 
in the alprazolam-treated group (Table 1). 
BN 52021 totally blocked the bypotensive effect of tbe 
1-nmol/kg dose of PAF (Table 2) and effectively atten-
uated but never completely abolished the decrease in 
MAP produced by tbe 3-nmol/kg dose (Fig. 2). Tbe 
increase in heart rate induced by P AF was blocked by 
TABLE L Base-line values of gross cardiovascular 
variables before PAF administration in BN 52021-, 
SDZ 63-441-, or alprazolam-treated and control rats 
MAP, HR, CI, TPRI, Group n ml-min-1 • mmHg-mJ-1 • 
mmHg beats/min kg-1 min.kg 
Control 8-14 118±4 376±12 370±47 0.30±0.03 
BN 52021 9 112±3 414±20 451±28 0.26±0.02 
SDZ 63-441 4 118±6 411±43 349±17 0.34±0.01 
Alprazolam 10 103±3* 412±14* NT NT 
Values are means ±SE; n, no. of rats. MAP, mean arterial pressure; 
HR, heart rate; CI, cardiac index; NT, not tested; TPRI, total periph-
eral resistance index. Measurements were made 20 min after iv injec-
tion of saline, 15 mg/kg BN 52021, or 3 mg/kg alprazolam, and 2 min 
after 1 mg/kg SDZ 63-441. This time point denotes situation immedi-
ately before administration of 1st dose of PAF. • Significance from 
control group, P < 0.05 (Dunnett's test). 
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TABLE 2. Modulation of the hemodynamic responses 
to I nmol/ kg PAF by the PAF antagonists 
BN 52021, SDZ 63-441, and alprazolam 
MAP, HR, Cl, TPRI, Group n 
mmHg beats/min mJ.min-
1
· mmHg.ml-1· 
kg-1 min.kg 
PAF 12 -35±5 +89±19 +14±21 -0.11±0.03 
PAF after BN 4 +8±5* +29±14 +104±30t -0.02±0.01 
52021 
P AF after SDZ 4 0±3* +24±23 +66±11 -0.05±0.01 
63-441 
PAF after 10 -46±5 +104±24 NT NT 
alprazolam 
Values are means ±SE and represent maximum changes 30 s to 2 
min after PAF administration. MAP, mean arterial pressure; HR, heart 
rate; CI, cardiac index; TPRI, total peripheral resistance index; NT, 
not tested. lntravenous injections of 15 mg/kg BN 52021 or 3 mg/kg 
alprazolam were given 20 min before PAF. SDZ 63-441 was adminis-
tered 2 min before PAF. Compared with PAF alone: * P < 0.01; t P < 
0.05 (Dunnett's test). 
BN 52021 (Fig. 2, Table 2). BN 52021 totally abolished 
the cardiac depressant effect of the 3-nmol/kg dose of 
P AF but failed to attenuate the PAF -induced decrease 
in TPRI (Fig. 2). After BN 52021, the 1-nmol/kg dose of 
P AF increased cardiac index in all animals. In the BN 
52021-treated rats, the peak increase in cardiac index 
( + 104 ± 30 ml. kg-1 • min-I, n = 4, P < 0.01 vs. control) 
was reached 2 min after P AF injection, and the cardiac 
index was still significantly elevated ( +67 ± 45 ml· 
min-1 .kg-1, n = 4, P < 0.05 vs. control) 10 min after the 
P AF injection. 
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A 1-mg/kg intravenous injection of SDZ 63-441 
blocked the hypotensive effect of 1 nmol/kg P AF and 
attenuated the tachycardia (Table 2). After SDZ 63-441 
treatment, P AF increased cardiac index in all animals. 
The peak increase in cardiac index by P AF in the SDZ 
63-441-treated ratswas +66 ± 11 ml.min-1 .kg-1 (n = 4, 
P < 0.01 vs. control). 
A 3-mg/kg intravenous injection of alprazolam bad no 
effect on the hypotensive and tachycardiac responses to 
0.3-3 nmol/kg PAF (Table 2). 
Effects of PAF on organ blood flow and vascular resist-
ance. Figure 3 demonstrates an original tracing of the 
effect of P AF on arterial pressure and regional blood 
flow. The 0.3-nmol/kg dose of PAF, which had no sig-
nificant effect on MAP, induced a profound increase in 
mesenteric blood flow with no effect on renal or hind-
quarter vessels (Figs. 3 and 4). The higher dose (1 nmol/ 
kg) decreased arterial pressure and renal blood flow, 
increased hindquarter blood flow, and initially increased 
but then decreased mesenteric blood flow. The maximum 
responses were reached 30-60 s after the injection and 
subsided within 5 min after the low doses, whereas after 
the higher doses, blood flow in all three vascular beds 
was decreased over a period of 5-10 min. 
PAF (0.1-1 nmol/kg) decreased mesenteric vascular 
resistance in a dose-related manner (Fig. 4), whereas the 
highest dose (3 nmol/kg) induced primarily mesenteric 
vasoconstriction. The renal vascular resistance was sig-
nificantly decreased after the 1- and 3-nmol/kg doses of 
PAF, with the maximum decrease (-38 ± 6%, P < 0.01 
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FIG. 2. Effect of 3 nmol/kg PAF on mean arterial pressure (MAP), heart rate (HR), cardiac index (Cl), and total 
peripheral resistance index (TPRI) in control rats and rats intravenously injected with 15 mg/kg BN 52021 20 min 
before PAF administration. Left: each graph represents base-line values of MAP, HR, CI, or TPRI in control and BN 
52021-treated rats. Right: each graph demonstrates changes of MAP and HR calculated from these base-line values 
immediately before PAF administration. Values indicate means ± SE. Asterisks indicate statistical significance 
between groups by Kruskal-Wallis test. 
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FIG. 3. A representative chart recording of effect of 0.3-1 nmol/kg 
PAF on arterial pressure (AP) and organ blood flow in hindquarter 
(HQ), renal (R), and mesenteric (M) vessels of conscious rat. 
vs. saline) being reached with the 1-nmol/kg dose (Fig. 
4). Hindquarter vascular resistance was dose dependently 
decreased by the 1- and 3-nmol/kg doses of PAF. The 
maximum effect (-56 ± 7%, P < 0.01 vs. saline) was 
achieved by the highest dose (Fig. 4). At no dose or time 
point was there an increase in hindquarter vascular 
resistance. 
Effect of BN 52021 on regional vascular responses to 
PAF. A 15-mg/kg dose of BN 52021 had no influence on 
the resting Ievel of organ blood flow (Fig. 4). Pretreat-
ment with BN 52021 attenuated the increase in mesen-
teric blood flow and decrease in mesenteric vascular 
resistance produced by the 0.3-nmol/kg dose of P AF but 
had no significant effect on the mesenteric vasodilator 
responses produced by the other doses of PAF (Fig. 4). 
The mesenteric vasoconstrictor effect of the 3-nmol/kg 
dose of PAF was significantly attenuated but not com-
pletely blocked by BN 52021. The renal vasodilation 
induced by the 1-nmol/kg dose of PAF was totally 
blocked by BN 52021 (Fig. 4), and the hindquarter vas-
odilation produced by the 1- and 3-nmol/kg doses of PAF 
was significantly attenuated by BN 52021 (Fig. 4). 
DISCUSSION 
The present report is an extension of our previous 
efforts to elaborate the mechanisms involved in the 
cardiovascular actions of P AF in the conscious rat. W e 
have chosen the rat as the experimental model for these 
studies, since in this species no apparent respiratory 
effects are associated with the hemodynamic responses 
to PAF. In addition, at PAF doses used in the present 
experiment, rat platelets are resistant to PAF -induced 
aggregation (24), and therefore the hemodynamic effects 
of P AF in the rat are not confounded by blood cell 
aggregation commonly seen in other species (e.g., rabbit, 
pig, guinea pig, and dog). 
Intravenously infused P AF decreased blood pressure 
and increased heart rate in conscious rats. These results 
are in agreement with the hypotensive responses to P AF 
described previously in the conscious rat (11, 31) andin 
a nurober of other species such as guinea pigs, dogs, 
domestic pigs, and rabbits (for review see Ref. 8). The 
hypotensive effect of the low doses of P AF seems to be 
due to peripheral vasodilation, since TPRI was mar kedly 
decreased at the peak of the hypotensive response while 
the cardiac index did not change. Opposite to the effect 
of the low doses of PAF, the 3-nmol/kg dose produced a 
sustained decrease in cardiac index despite the promi-
nent tachycardic response. At this dose a transien t fall 
followed by sustained elevation of TPRI was also ob-
served. Thus our results are in accordance with the 
cardiodepressant and vasoconstrictor responses to high 
systemic doses of PAF in the anesthetized dog (27, 30) 
and in the pentobarbital sodium-anesthetized rat (12). 
In vitro sturlies also indicated a cardiac depressant action 
of PAF at very high concentrations (5, 18, 26). On the 
isolated human papillary muscle, PAF produced a tran-
sient increase of contractility followed by a prolonged 
depression (1). In the intact domestic pig, intracoronary 
infusion of P AF first dilated and then constricted the 
coronary arteries (10). 
In the present study systemic injections of PAF dose 
dependently decreased renal and hindquarter vascular 
resistance and in the mesenteric region induced a bi-
phasic response: a vasodilation in the low doses followed 
by a constriction by higher doses. The regional hemo-
dynamic effects of P AF resemble those obtained by Faber 
et al. (7), who found hypotensive, tachycardic, and renal, 
mesenteric, and hindquarter vasodilator responses after 
intravenous (50-500 ng/rat) injection of the antihyper-
tensive polar renomedullary Iipids (APRL) in the con-
scious rat. However, the regional hemodynamic effects 
of pure synthetic P AF in conscious rats have not been 
reported previously. In the anesthetized spontaneously 
hypertensive rat (SHR), decreases in blood flow to brain, 
heart, kidneys, lungs, and spieen accompanied the sys-
temic hypotension induced by continuous intravenous 
infusion of high doses of PAF (0.3-1 ~Lg· kg-1 • min-1 
equaling 0.6-2 nmol. kg- 1 • min-1), but the changes in 
vascular resistance were not reported (12). In a more 
recent study, 0.06 nmol/kg PAF produced mesenteric 
vasodilation in anesthetized SHR (19). In the dog, PAF 
produced renal vasoconstriction (2, 30) but vasodilation 
when infused into the femoral artery (27). Direct injec-
tion of P AF into the coronary circulation of anesthetized 
domestic pig produced a biphasic change in coronary 
blood flow: vasodilation followed by vasoconstriction (9). 
The mesenteric vasodilation was observed at PAF 
doses that had no effect on systemic arterial pressure or 
organ blood flow in the renal or hindquarter regions. 
Analogaus to our findings, the mesenteric artery seemed 
tobe the mostsensitive organ for the vasodilator effect 
of APRL in the rat (7). Dose-dependent mesenteric 
vasodilation after injections of the P AF precursor 1-
palmityl-2-acetyl-glycerol was reported in anesthetized 
SHR (19). In the present study, the mesenteric vascula-
ture responded to PAF with a biphasic response: after 
the initial vasodilation a vasoconstrictor response was 
found at high doses of PAF. In a recent study in the rat, 
high doses of PAF (2 J.Lg/rat equaling --10 nmol/kg) 
induced bowel necrosis (15). Therefore, our finding sug-
gests that the pathological changes found in the intestine 
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(15) are at least in part the result of ischemia due to a 
secondary mesenteric vasoconstriction. Furthermore, the 
increase in mesenteric vascular resistance and reduction 
of mesenteric blood flow produced by high doses of P AF 
closely resembles the changes in mesenteric blood flow 
in acute systemic anaphylaxis (32). Thus ovalbumin 
challenge in the presensitized conscious rat results in 
prolonged decrease in mesenteric blood flow even after 
recovery from the early hypotensive phase (32), indicat-
ing that vasoconstriction is maintained. Because P AF is 
known to be released in the systemic circulation during 
acute anaphylaxis, systemic Iupus erythematosus, and 
intravascular coagulation in humans (5), our data further 
contribute to the possibility of P AF -mediated darnage to 
splanchnic blood flow in situations in which large 
amounts of P AF would be rapidly released. 
The PAF antagonist BN 52021 effectively blocked the 
hypotensive, tachycardic, and cardiac depressant effects 
of P AF as well as the decrease in TPRI produced by the 
1 nmoljkg dose of PAF. We have recently reported (10) 
•• 
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FIG. 4. Effect of 0.1-3 nmol/kg PAF on regional 
blood flow and vascular resistance in conscious rats. 
Left: each graph denotes base-line Ievels of blood 
• flow or vascular resistance immediately before PAF 
administration; right: maximum changes 30 s after 
PAF. BN 52021 was injected intravenously 20 min 
before P AF administration. V alues indicate means 
± SE. Asterisks and a denote statistical significance 
by Student-Newman-Keuls test. 
Q 
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that 5 mg/kg BN 52021 also totally blocked the increase 
in pulmonary arterial pressure and vascular resistance 
induced by PAF administration in the neonatal pig. BN 
52021 both prevented and reversed the hypotension, 
hemoconcentration, and plasma extravasation produced 
by PAF in the rat (24) and antagonized PAF -induced 
bronchoconstriction in the guinea pig (4). Because BN 
52021 is known tobe a specific antagonist of PAF recep-
tors (4, 24), our results indicate a direct stimulation of 
the P AF receptors as a main mechanism of its hypoten-
sive and cardiodepressant actions. In an earlier study, 
specific cholinergic, histaminergic, or ß-adrenoceptor an-
tagonists had no blocking capacity against the hypoten-
sive effect of PAF in the rat (17), whereas in the anes-
thetized dog or domestic pig the hypotensive effect of 
PAF is prevented by indomethacin (8, 27). The tachy-
cardic effect of P AF, on the other hand, is blocked by 
the ß-adrenoceptor blocker propranolol (31) and is prob-
ably mediated by a reflex activation of the sympathe-
toadrenomedullary system due to the systemic hypoten-
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sion (11, 20). Thus in the pithed rat, which totally lacks 
the central nervous and spinal autonomic control, P AF 
produced hypotension with no effect on heart rate or 
plasma catecholamines (11). Therefore, the attenuation 
of the tachycardic effect of P AF by BN 52021 in our 
study can be explained by the blockade of PAF-induced 
hypotension rather than by a direct inhibition of cardiac 
P AF receptors. 
In the present study only the 3 nmol/kg dose of P AF 
decreased cardiac output, whereas the lower doses had 
no consistent effect on cardiac index per se; half of the 
animals reacted to the 1-nmol/kg dose with a transient 
increase in cardiac index, whereas in the remaining ani-
mals PAF decreased cardiac index. BN 52021 totally 
blocked the cardiac depressant effect of the high dose of 
P AF, even though the hypotensive response was only 
partially attenuated. P AF receptor blockade with BN 
52021 or SDZ 63-441 also modified the effect of the 1-
nmol/kg dose of PAF so that, after PAF receptor block-
ade, this dose of PAF induced solely a sustained increase 
in cardiac index in each animal studied. BN 52021 and 
SDZ 63-441 had no intrinsic activity of their own on the 
cardiovascular system and both of these compounds are 
selective antagonists of the P AF receptors, at the doses 
used in the present study (4, 13, 19, 24). Therefore, the 
increase in cardiac index after BN 52021 or SDZ 63-441 
treatment is likely to be due to an interaction with the 
P AF receptors. U nmasking of a positive inotrophic ac-
tion of P AF by the receptor antagonists could insinuate 
the existence of two different subclasses of P AF receptors 
that mediate opposite effects on the cardiac function. 
This might explain the variable responses of P AF on 
cardiac function in in vitro sturlies (1, 11, 18, 26). 
PAF receptor blockade by BN 52021 had a differential 
degree of antagonism against the regional hemodynamic 
effects of PAF, yet the hindquarter effects were most 
effectively blocked by BN 52021 with only a partial 
attenuation of the renal and especially the mesenteric 
responses. Evidence for a direct action of P AF on blood 
vessels has also been shown in the dog in which the renal 
vasoconstrictor effect of intrarenally infused P AF was 
not affected by blockers on a-adrenergic or angiotensin 
II receptors but was enhanced by cycloxygenase inhibi-
tors (2). The coronary constrictor effect of PAF in the 
pig was blocked by indomethacin and thus probably 
mediated by cycloxygenase metabolites of arachidonic 
acid, but the coronary dilationwas unaffected by cyclox-
ygenase inhibitors (10). Further evidence in support for 
arachidonic acid metabolites as mediators of the vaso-
constrictor effects of P AF was recently provided by Stew-
art and Piper (26), who found attenuation ofthe coronary 
constrictor effect of P AF in the isolated rat heart by 
cycloxygenase and lipoxygenase inhibitors. The potential 
role of the arachidonic acid metabolites in the regional 
hemodynamic responses to P AF in the conscious rat 
remains to be further studied. However, in the conscious 
rat, P AF produced predominantly vasodilator responses 
in all vascular beds despite the potential generation of 
vasoconstrictor mediators such as thromboxane A2 and 
leukotrienes (11, 26). However, indomethacin did not 
block the hypotension produced by PAF in the rat (11). 
In contrast to the recent in vitro findings, our study 
failed to show any PAF-antagonistic effect of alprazolam. 
This triazolobenzodiazepine was shown to block PAF-
induced aggregation of human, guinea pig, and canine 
platelets (2, 6, 16). The renal vasoconstrictor effect of 
P AF in the anesthetized dog was attenuated by alprazo-
lam and by the serotonin blocker methysergide (2). In 
the conscious rat, however, alprazolam at a relatively 
high dose (3 mg/kg iv), which already exerted typical 
intrinsic activity of a sedative (e.g., hypotension), had no 
effect on the cardiovascular responses to PAF. Species 
differences might account for the discrepancy between 
our finding and the previous study on dogs in which 
serotonin release from platelets might contribute to the 
PAF actions (2). Because most of the previous reports 
using alprazolam have been about platelets (2, 6, 16), 
and rat platelets are known tobe resistant to PAF (24), 
the Iack of an antagonistic effect of alprazolam in the 
rat is not unexpected. 
In summary, the results indicate that the systemic 
hemodynamic changes induced by P AF are due to a 
combination of cardiac and vascular derangements. P AF 
is a potent vasodilator of mesenteric > hindquarter = 
renal vessels at low doses and a cardiac depressant at 
high doses. The PAF antagonist BN 52021 and SDZ 63-
441 effectively blocked the cardiac depressant effect of 
PAF, and BN 52021 attenuated, in part, the regional 
vascular responses (hindquarter > renal>> mesenteric). 
Thus specific PAF -antagonists such as BN 52021 or SDZ 
63-441 might be used as therapeutic agents in disease 
states such as endotoxemia, anaphylaxis, and other im-
mune reactions in which increased release of P AF is a 
contributing factor to key hemodynamic derangements. 
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